Envisagenics reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions.
Envisagenics has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in June 2024.
Envisagenics's investors include Madrona, Bristol-Myers Squibb, National Institutes of Health, Red Cell Partners, SV Angel.
Envisagenics is headquartered in Long Island City, United States.
Envisagenics reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions.
Envisagenics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Envisagenics — Funding & Investors." VCBacked, June 4, 2024, https://www.vcbacked.co/company/envisagenics. Accessed September 2, 2026.
VCBacked. (2024). Envisagenics — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/envisagenics
{{cite web |title=Envisagenics — Funding & Investors |url=https://www.vcbacked.co/company/envisagenics |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated